Cardiovascular development and function in relation to nuchal translucency.

Cardiovascular development and function in relation to nuchal translucency. - cardiovascular status and nuchal translucency.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29933

Enrollment

150

Registered

2007-03-01

Start date

2006-08-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

increased nuchal translucency

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: group 1: singleton pregnancy Crown Rump Length between 45 mm and 79 mm. increased nuchal translucency (> p 95) group 2: singleton pregnancy Crown Rump Length between 45 mm and 79 mm. nuchal translucency

Exclusion criteria

Exclusion criteria: twin pregnancy Crown Rump Length smaller than 45 mm or bigger than 79 mm.;use of teratogenical medication skeletal dysplasia of the fetus

Design outcomes

Primary

Measure	Time frame
Differences in cardiac function between fetuses with normal nuchal translucency and fetuses with increased nuchal translucency. Differences in cardiovascular development between wild type mouse embryo's and trisomy 16 mouse embryo's/ VEGF 120/120 mouse embryo's. Differences in cardiovascular development between human fetuses with normal nuchal translucency and increased nuchal translucency.	—

Countries

Netherlands

Outcome results